吗拉宗盐酸盐 | 50321-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 吗拉宗盐酸盐
• 英文名称: 1,5-dimethyl-4-(3-methyl-2-phenyl-morpholinomethyl)-2-phenyl-1,2-dihydro-pyrazol-3-one; hydrochloride
• 英文别名: 1,5-Dimethyl-4-(3-methyl-2-phenyl-morpholinomethyl)-2-phenyl-1,2-dihydro-pyrazol-3-on; Hydrochlorid；Morazone hydrochloride；1,5-dimethyl-4-[(3-methyl-2-phenylmorpholin-4-yl)methyl]-2-phenylpyrazol-3-one;hydrochloride
• CAS: 50321-35-2
• 化学式: C₂₃H₂₇N₃O₂*ClH
• 分子量: 413.947
• InChiKey: QPNQBCBHTTYDEN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.87
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  37.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  吗拉宗 在 盐酸 作用下， 以 乙醚 为溶剂， 生成 吗拉宗盐酸盐
  参考文献：
  名称：

  Mrongovius; Neugebauer; Ruker, European Journal of Medicinal Chemistry, 1984, vol. 19, # 2, p. 161 - 166

  摘要：

  DOI：

文献信息

• [EN] SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS<br/>[FR] SYNTHÈSE DE LACTONES D'ACIDE RÉSORCYLIQUE UTILES EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：UNIV STRASBOURG

  公开号：WO2009091921A1

  公开（公告）日：2009-07-23

  Disclosed are macrocyclic compounds of formulae I, I', II, II', III, III', IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

  公开的是式I、I'、II、II'、III、III'、IV和V的大环化合物，它们是pochonin resorcylic acid lactones的类似物，包括这些化合物的药物组合物，以及包括这些化合物用于治疗由激酶和热休克蛋白90 HSP90介导的疾病的方法和用途。
• 1,3-Bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
  申请人：——

  公开号：US20030232877A1

  公开（公告）日：2003-12-18

  The invention relates to compounds, pharmaceutical compositions and methods of using compounds of the general formula 1 or its pharmaceutically acceptable salt or ester, wherein the substituents are defined in the application.

  这项发明涉及通式1的化合物、药物组合物和使用该化合物的方法，其中取代基在申请中定义。
• METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D
  申请人：Stein Donald G.

  公开号：US20110306579A1

  公开（公告）日：2011-12-15

  Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D.

  本文描述了用于治疗或预防神经系统损伤的组合物和方法。具体而言，这些方法和组合物涉及使用至少一种神经保护类固醇，如孕激素，和维生素D。
• [EN] NOVEL SALT FORMS OF POORLY SOLUBLE PROBUCOL ESTERS AND ETHERS<br/>[FR] NOUVELLES FORMES DE SELS D'ETHERS ET D'ESTERS DE PROBUCOL FAIBLEMENT SOLUBLES
  申请人：ATHEROGENICS INC

  公开号：WO2004007423A1

  公开（公告）日：2004-01-22

  Organic amine salts of compounds of formula (I), and their pharmaceutically acceptable salts, and uses in medical therapy are provided.

  提供了公式（I）化合物的有机胺盐及其药用可接受的盐，并用于医学治疗。
• 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
  申请人：Atherogenics Pharmaceuticals, Inc.

  公开号：US20030236298A1

  公开（公告）日：2003-12-25

  It has been discovered certain 1,3-bis-(substituted-phenyl)-2-propen-1-ones, including compounds of formula (I) inhibit the expression of VCAM-1, and thus can be used to treat a patient with a disorder mediated by VCAM-1. Examples of inflammatory disorders that are mediated by VCAM-1 include, but are not limited to arthritis, asthma, dermatitis, cystic fibrosis, post transplantation late and chronic solid organ rejection, multiple sclerosis, systemic lupus erythematosis, inflammatory bowel diseases, autoimmune diabetes, diabetic retinopathy, rhinitis, ischemia-reperfusion injury, post-angioplasty restenosis, chronic obstructive pulmonary disease (COPD), glomerulonephritis, Graves disease, gastrointestinal allergies, conjunctivitis, atherosclerosis, coronary artery disease, angina and small artery disease.

  已经发现了某些1,3-双-(取代苯基)-2-丙烯-1-酮，包括公式(I)化合物抑制VCAM-1的表达，因此可用于治疗受VCAM-1介导的疾病的患者。VCAM-1介导的炎症性疾病的例子包括但不限于关节炎、哮喘、皮炎、囊性纤维化、移植后晚期和慢性实体器官排斥、多发性硬化症、系统性红斑狼疮、炎症性肠病、自身免疫性糖尿病、糖尿病视网膜病变、鼻炎、缺血再灌注损伤、血管成形术后再狭窄、慢性阻塞性肺疾病（COPD）、肾小球肾炎、格雷夫斯病、胃肠道过敏、结膜炎、动脉粥样硬化、冠状动脉疾病、心绞痛和小动脉疾病。